Antti Vuolanto
Chief Executive Officer bij HERANTIS PHARMA OYJ
Profiel
Antti Vuolanto is the founder of Targovax Oy, which was founded in 2009.
He held the title of Chief Operating Officer from 2014 to 2015.
Dr. Vuolanto is currently the Chief Executive Officer at Herantis Pharma Oyj since 2018.
In his former positions, he worked as a Principal at Mobidiag Oy and Medicel Oy.
He also served as the Executive Vice President at Circio Holding ASA from 2015 to 2017 and as the Chief Operating Officer at Valo Therapeutics Oy from 2017 to 2018.
Dr. Vuolanto obtained his doctorate degree from Aalto University School of Science & Technology in 2004.
Actieve functies van Antti Vuolanto
| Bedrijven | Functie | Begin |
|---|---|---|
| HERANTIS PHARMA OYJ | Chief Executive Officer | 22-07-2022 |
Eerdere bekende functies van Antti Vuolanto
| Bedrijven | Functie | Einde |
|---|---|---|
Valo Therapeutics Oy
 Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Chief Operating Officer | 01-02-2018 |
| CIRCIO HOLDING ASA | Corporate Officer/Principal | 01-02-2017 |
Targovax Oy
 Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Founder | 01-07-2015 |
Mobidiag Oy
 Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | Corporate Officer/Principal | - |
Medicel Oy
 Medicel Oy Information Technology ServicesTechnology Services Medicel Oy develops and provides software services for reverse engineering and modeling of biochemical pathways for drug discovery and validation. The company's product platforms include Medicel Integrator, Medicel Explorer, and Medicel Services. Medicel was founded in March 2001 and is headquartered in Espoo, Finland | Corporate Officer/Principal | - |
Opleiding van Antti Vuolanto
| Aalto University School of Science & Technology | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CIRCIO HOLDING ASA | Health Technology |
| HERANTIS PHARMA OYJ | Health Technology |
| Bedrijven in privébezit | 4 |
|---|---|
Mobidiag Oy
Mobidiag Oy Miscellaneous Commercial ServicesCommercial Services Mobidiag Oy provides molecular diagnostic for infectious diseases. It develops and provides microarray-based Prove-it technology for early and diagnosis of life-threatening pathogenic microbes causing severe infections. Its Amplidiag product line comprises products for gastrointestinal pathogens and utilizes quantitative real-time polymerase chain reaction technology. The company was founded by Mart Saarma in 2000 and is headquartered in Espoo, Finland. | Commercial Services |
Medicel Oy
Medicel Oy Information Technology ServicesTechnology Services Medicel Oy develops and provides software services for reverse engineering and modeling of biochemical pathways for drug discovery and validation. The company's product platforms include Medicel Integrator, Medicel Explorer, and Medicel Services. Medicel was founded in March 2001 and is headquartered in Espoo, Finland | Technology Services |
Targovax Oy
Targovax Oy Pharmaceuticals: MajorHealth Technology Targovax Oy focuses on the development and commercialization of targeted cancer immunotherapy. It is a biotechnology company with novel immunotherapy platform that is based on engineered oncolytic viruses armed with potent immune-stimulating transgenes. The firm's products induce a tailored response by the immune system directed at each patient’s unique cancer cells. The company was founded by Pekka Ilmari Simula and Antti Vuolanto in 2009 and is headquartered in Helsinki, Finland. | Health Technology |
Valo Therapeutics Oy
Valo Therapeutics Oy Pharmaceuticals: MajorHealth Technology Valo Therapeutics Oy is an immunotherapy company based in Helsinki, FI. The Finnish company is focused on developing innovative immunotherapy approaches against cancer and infectious disease. Valo Therapeutics's lead platform, PeptiCRAd, was developed out of the laboratory of Professor Vincenzo Cerullo at the University of Helsinki. The company is also developing PeptiEnv and PeptiVax, among other neoantigen strategies, in collaboration with Professor Cerullo. The company's PeptiChip technology enables the rapid and accurate identification of tumor antigens. Valo Therapeutics is also developing antigen-coated oncolytic viruses as anti-cancer therapeutic vaccines. The company was founded in 2016, and Paul Grant Higham has been the CEO of the company since 2020. | Health Technology |
